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Summary
Objective: Given the significant impact epilepsy can have on health-related qual-
ity of life (HRQoL) of individuals with this condition and their families, there is
great clinical interest in evidence-based psychological treatments aimed at enhanc-
ing well-being in people with epilepsy (PWE). An evaluation of the current evi-
dence is needed to assess the effects of psychological treatments for PWE on
HRQoL outcomes to inform future therapeutic recommendations and research
designs.
Methods: The operational definition of psychological treatments included a broad
range of interventions that use psychological or behavioral techniques designed to
improve HRQoL, psychiatric comorbidities, and seizure frequency and severity
for adults and children with epilepsy. A systematic literature search was con-
ducted in line with Cochrane criteria for randomized controlled trials (RCTs) and
quasi-RCTs investigating psychological treatments and using HRQoL outcome
measures as primary or secondary outcome measures. Standard methodological
procedures required by the Cochrane Collaboration were used for data collection
and analysis.
Results: Twenty-four completed RCTs were included in this review (2439 partic-
ipants). Based on satisfactory methodological homogeneity, data from 9 studies
(468 participants) providing Quality of Life in Epilepsy-31 (QOLIE-31) outcomes
were pooled for meta-analyses, showing significant mean changes for QOLIE-31
total score and 6 subscales. The significant mean changes of QOLIE-31 total
score (mean improvement of 5.68 points; 95% confidence interval = 3.11-8.24,
P < .0001) and 3 subscales (emotional well-being, energy/fatigue, overall quality
of life [QoL]) exceeded the threshold of minimally important change, indicating a
clinically meaningful postintervention improvement of QoL. Overall, the meta-
analysis quality of evidence was characterized as “moderate” due to the risk of
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bias present in 8 of the 9 included studies (Handbook for Systematic Reviews of
Interventions, Version 5.1.0, 2011, Chapters 8 and 12). A narrative synthesis was
conducted for all trials and outcomes that were not entered in the meta-analysis.
Significance: These results provide moderate-quality evidence that psychological
treatments for adults with epilepsy may enhance HRQoL in people with epilepsy.
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1 | INTRODUCTION
People with epilepsy (PWE) are at increased risk of psychi-
atric comorbidities compared to the general population and
nonneurological medical conditions,3,4 as well as to people
with other neurological diseases,5 and the profound physi-
cal, psychological, and social consequences of epilepsy
impact health-related quality of life (HRQoL). HRQoL is a
patient-reported outcome measure that encompasses several
domains, including physical, social, emotional, and school/
work.6–8 Epilepsy-specific HRQoL measures are more sali-
ent to specific aspects of epilepsy and its treatments and
thus constitute a particularly sensitive and responsive
patient-reported outcome for PWE.9,10 Unlike in patients
with psychogenic nonepileptic seizures, there remains a sig-
nificant relationship between HRQoL and epilepsy severity
markers when psychopathology is introduced as a covari-
ate.11 Both population-based and experimental studies in
human and animal models have demonstrated a robust rela-
tionship between seizures and psychiatric disorders. This
relationship has been interpreted by some as a sign of bidi-
rectionality, suggesting that psychological/psychiatric disor-
ders can be consequences of as well as predispose to or
precipitate epilepsy and that psychiatric disorders can exac-
erbate seizures, leading to a vicious cycle.12–14 Other
authors, however, criticize the interpretation of a varying
temporal relationship as evidence of a bidirectional rela-
tionship.15 Overall, these findings have prompted further
research on the use and benefit of psychological treatments
for PWE.
A wide array of psychological approaches have been
used to target the enhancement of HRQoL, seizure man-
agement, and reduction of psychiatric comorbidity in chil-
dren and adults with epilepsy. Cognitive and behavioral
treatments, mind-body therapies, and educational interven-
tions are the most common approaches.16 A 2008 Cochrane
Review17 assessed the findings of 16 randomized con-
trolled trials (RCTs) and quasi-RCTs of psychological
treatments in PWE and found no reliable evidence for the
efficacy of psychological treatments in terms of seizure
control. Over the past decade, additional trials with sub-
stantially improved designs have become available that
have been critically appraised in a number of recent
reviews,16,18 providing growing evidence for the positive
effects of psychological treatments on wider HRQoL, psy-
chiatric symptoms (ie, anxiety, depression), psychological
functioning (ie, self-management), and seizure control in
PWE.
A Psychology Task Force was set up under the Medi-
cal Therapies Committee comprising experts selected by
the International League Against Epilepsy (ILAE) to
review and reappraise the role of psychological treat-
ments for PWE. The purpose of this review was twofold.
First, we aimed to examine the effectiveness of psycho-
logical treatments on HRQoL in PWE. To address this,
the Task Force was charged with performing a meta-
analysis of RCTs and quasi-RCTs investigating the effects
of psychological treatments on HRQoL in PWE. Second,
we explored the effects of psychological treatments on psy-
chiatric symptoms and seizure control in these trials. This
article summarizes the findings of a Cochrane Review that
is the outcome of an international collaboration process and
has been approved by the ILAE Executive Committee.19
Key Points
• A systematic search of databases for RCTs inves-
tigating psychological treatments using HRQoL
outcome measures yielded 24 RCTs
• Data from 9 studies were pooled for meta-
analyses showing significant mean changes for
Quality of Life in Epilepsy-31 total score and 6
subscales
• These results provide evidence of moderate qual-
ity that psychological treatments for adults with
epilepsy may enhance HRQoL in PWE
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1.1 | Operational definition of psychological
treatments for PWE
The operational definition of psychological treatments
includes a broad range of interventions that use psychologi-
cal techniques for children and adults with epilepsy. These
interventions may be given singly or in combination, either
alone or as add-on to antiepileptic drugs, and can be cate-
gorized into 4 groups:
1. Psychological interventions. These interventions are
defined as interventions that are based on a theory of
psychotherapy. Examples include cognitive-behavioral
and/or behaviorally based interventions and mindful-
ness-based interventions (such as acceptance and com-
mitment therapy). Common therapeutic strategies
include counseling, cognitive strategies such as thought
restructuring or acceptance, conditioning, behavioral
activation, systematic desensitization, relaxation, and
behavioral countermeasures (such as breathing and visu-
alization techniques) at aura onset applied by the
patient. Other therapeutic approaches may include
family systems therapy and motivational interviewing.
2. Self-management/family management. This is defined as
activities or steps that an individual or family can per-
form that are known to either control the frequency of
seizures, or promote the well-being of the person with
seizures. Activities or steps can encompass individual,
family, community, or health care system domains.
Behaviors include relaxation, physical exercise, and
coping skills.
3. Adherence interventions. These are defined as efforts to
assist patients to adhere to the advice of health care pro-
viders, including taking prescribed self-administered
medications, following a ketogenic diet, and avoiding
seizure triggers. Medication taking can be broken down
into several components, including optimal dose timing
and frequency of dosing. Strategies to improve adher-
ence include visual reminders, organizational strategies,
behavioral strategies (eg, pair medication with a daily
routine), and problem-solving around adherence barri-
ers.
4. (Psycho-)educational interventions. These are defined as
interventions that aim to increase knowledge about epi-
lepsy, its comorbidities, and its treatments or the func-
tions and activities of the brain.
2 | MATERIALS AND METHODS
2.1 | Types of studies
Because HRQoL is the primary outcome of interest in this
review, we included all RCTs and quasi-RCTs that
investigated psychological treatments, as operationally
defined, for children and adults with epilepsy and that
reported validated HRQoL outcome measures as primary or
secondary outcome measures. Other quality of life (QoL)-
related parameters, such as symptoms of psychiatric comor-
bidities and seizure-related outcome measures, were also
interpreted in the included studies.
2.2 | Search methods and identification of
studies
The process of study selection is displayed in Figure 1.
The following databases were searched on September 20,
FIGURE 1 Flow chart of study selection. HRQoL, health-related
quality of life; QOLIE, Quality of Life in Epilepsy
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2016 for RCTs and quasi-RCTs investigating psychological
treatments without language restrictions: Cochrane Epilepsy
Group Specialized Register, Cochrane Central Register of
Controlled Trials via the Cochrane Register of Studies
Online, MEDLINE (Ovid) from 1946 onward, and Psy-
INFO (EBSCO) from 1887 onward. The search strategies
for each of these databases are shown in Appendices S1-
S4. ClinicalTrials.gov was searched using the search terms
(psychological OR psychotherapy) AND epilepsy. The
World Health Organization International Clinical Trials
Registry Platform was searched using the search terms
(psychological OR psychotherapy) AND epilepsy. In addi-
tion, the reference lists of retrieved studies and relevant
reviews were reviewed to identify additional reports of rel-
evant studies.
In line with the standard Cochrane selection process,20
all titles and abstracts were reviewed independently to
determine their relevance by 2 review authors, a neurology
resident specializing in epilepsy and psychotherapy (R.M.)
and a clinical psychologist specializing in neuropsychology
and psychotherapy (V.T.), resolving disagreements through
discussion with the wider group of authors or the Epilepsy
Review Group. Relevance was defined by the operational
definition of psychological treatments for PWE and the
inclusion of a validated HRQoL measure as a primary or
secondary outcome. The full text of all studies was exam-
ined if initial screening suggested that they may be suitable
for inclusion. Reasons for exclusion at the level of full-text
review are included in Figure 1.
2.3 | Data analysis and management
Data of all included studies were extracted by R.M. and
V.T. independently using an electronic Cochrane data col-
lection form that had been adapted and pilot tested to fit
the scope of this review.21 Risk of bias (ROB) assessment
was conducted using the Cochrane Collaboration’s recom-
mended domain-based evaluation tool for randomized tri-
als.1 Critical assessments were made separately for type of
bias, namely selection bias, performance bias, detection
bias, attrition bias, reporting bias, and other sources of bias.
Discrepancies were resolved by mutual discussion. The
original investigators were contacted to request missing
information (eg, missing data) and clarification of method-
ology (eg, procedure of randomization). All study investi-
gators were contacted for their original protocols or
comparable documents to assess reporting bias.
Methodological heterogeneity, that is, variability in
study design,22 was assessed by R.M. and V.T. by examin-
ing the trial designs. Statistical heterogeneity was assessed
by applying the I2 and v2 tests. The authors judged a I2
result of >70% and a v2 result of P < .01 as indicative of
statistical heterogeneity.23 The types of interventions and
outcome measures used in the included studies were com-
pared by tabulation to assess whether meta-analysis was
appropriate. Meta-analysis was performed using Review
Manager software.24 The inverse variance method for con-
tinuous outcomes and a random-effects model was
employed. P < .05 was used as a statistical significance
level.
The mean change from baseline (standard deviation
[SD]) of the most commonly used HRQoL outcome mea-
sure was used for meta-analysis. For studies that were
excluded from the meta-analysis due to methodological
heterogeneity or insufficient data, the available postinter-
vention scores of validated HRQoL measures were com-
piled and presented via narrative synthesis. Postintervention
scores of secondary outcomes consisting of validated mea-
sures of psychiatric symptoms and seizure-related outcomes
were also compiled. The treatment effect for each continu-
ous outcome was expressed as a mean difference (MD)
with 95% confidence interval (CI). This review used the
GRADE approach25 to interpret findings.2
3 | RESULTS
3.1 | Description of studies
3.1.1 | Search results
The electronic search yielded 1155 titles from the data-
bases, with an additional 3 titles obtained from hand-
searching. Following the removal of duplicates, 877 titles
remained. Six hundred eight titles were excluded due to
irrelevance (that is, the titles clearly indicated that the stud-
ies were not related to the investigation of psychological
interventions for PWE). The authors reviewed the abstracts
of the remaining 269 titles for eligibility, leaving 52 full
texts to be assessed for inclusion. Twenty-one full texts
were excluded following full-text analysis (Figure 1).
Finally, this review included 24 completed RCTs from 31
publications. One publication26 described follow-up mea-
surements of the same study population27; it was therefore
not considered as a separate RCT (Figure 1).
3.1.2 | Psychological treatment methods
Psychological interventions
Table 1 groups the studies’ characteristics and intervention
components according to the operational definition of psy-
chological treatments. Intervention components may appear
in multiple groups due to the broad spectrum of treatment
techniques that are commonly used to realize the goals of
psychological interventions. The majority of psychological
interventions were cognitive and/or behaviorally based
interventions (11 studies, 46%) with the primary goal of
4 | MICHAELIS ET AL.
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treating depressive symptoms in adolescents and/or adults
with epilepsy, with varying levels of depression severity
defined as the inclusion criterion (n = 6, 54%).26–32 The
most common treatment strategies were cognitive restruc-
turing to address depressive thoughts and behavioral and
social activation. Two of these interventions (18%)
included mindfulness techniques.31,32 Only 1 study (9%)
targeted seizure frequency as a primary treatment goal.33
Treatment components included general and epilepsy-
specific stress management strategies. Four studies (36%)
focused on the primary treatment goal of improving
HRQoL. Three (27%) of them employed mindfulness inter-
ventions34–36 and evaluated mindfulness techniques in com-
bination with seizure management techniques. One of these
studies (4%)37 investigated motivational interviewing (MI),
which focused on enhancement of internal motivation for
coping with epilepsy.
(Psycho-)educational interventions
There were 7 studies (29%) examining the benefit of edu-
cational interventions. All of them comprised epilepsy
knowledge, advocacy topics, daily self-management behav-
iors, and psychosocial aspects primarily to enhance QoL
(n = 4, 57%),38–41 increase knowledge and coping,42
increase satisfaction of patients with information and sup-
port,43 or reduce drug-related problems.44
Self-management interventions
Three self-management/family management programs
(12%) were identified. One Internet-based self-management
program45 focused on improving adherence and perceived
stress levels. One consumer-driven psychoeducation
intervention46 focused on self-management behaviors by
discussing medical and psychosocial aspects of epilepsy
self-management and epilepsy-related communication.
Another self-management intervention47 applied similar
techniques but primarily evaluated the impact of the inter-
vention on HRQoL outcomes.
Adherence intervention
There was only 1 study (4%) that investigated an adherence
intervention using MI aiming to improve medication adher-
ence, medication-taking behaviors, seizure severity, and
HRQoL.48
Combined interventions
There were 2 combined interventions (8%). One combined
an epilepsy education group session covering epilepsy
knowledge and nurse-led personalized counseling with the
primary goal of enhancing QoL.49 The other was a home-
and telephone-based intervention50 combining self-manage-
ment and cognitive training to enhance QoL, mood, and
objective and subjective neurocognitive functions.
3.1.3 | Participants
The majority of studies examined interventions for adults
with epilepsy (75%); only 2 studies investigated educa-
tional interventions for children with epilepsy.38,42 One
study investigated a psychological intervention for adoles-
cents and young adults with epilepsy,29 2 studies investi-
gated mixed interventions for adolescents and adults,49,50
and 2 studies investigated educational interventions for
adolescents and adults.40,43
Severity of depressive symptoms was used as an inclu-
sion criterion in 5 studies (21%; see Table 1).26,27,29–32
One study only included adults with epilepsy and other
chronic comorbidities,44 because the intervention targeted
adverse effects stemming from drug interactions. Another
study50 included adolescents and adults with subjective
memory complaints, because the intervention included spe-
cial cognitive and memory training.
Seizure-related parameters (eg, minimum seizure fre-
quency) constituted an inclusion criterion in 6 studies
(25%; see Table 1).33–37,47 Altogether, the numbers of sei-
zure-free individuals and individuals with primary general-
ized epilepsy were comparably small in the study
populations of all included studies (mean number of partic-
ipants = 102). Many studies excluded individuals with
intellectual disability, and none of the studies reported
whether individuals experienced nocturnal or diurnal sei-
zures or whether individuals experienced seizure warnings.
3.1.4 | Trial design
Almost half of all study designs included a wait list control
(WLC) group (n = 11, 46%).28,31–33,37,38,40,42,43,45,46 Six
studies (25%) included an immediate active control group
(paper-based education intervention,39 supportive therapy,34
yoga,35 counseling as usual,29 pharmacotherapy with a
selective serotonin reuptake inhibitor,30 social support36).
The remaining 7 studies (29%) employed a usual care
(UC)/treatment as usual (TAU) control
group.26,27,31,41,44,48–50 The employment of a UC/TAU
design instead of a WLC group was especially reasonable
in long-term interventions (≥6 months).26,27,49
3.1.5 | Treatment delivery
Of the 24 studies, 11 examined group therapy
(46%),20,29,30,33,37,38,40–42,46,47 6 interventions (25%) were
delivered through individual sessions,9,15,26,27,43,44,48 and 4
interventions (17%) combined group therapy with individ-
ual sessions.34,35,49,50 Two studies (8%) used an Internet-
based delivery method,32,45 and 1 study (4%) used an Short
Message Service (SMS)-based approach.39 A specialized
team, usually consisting of medical (doctors, nurses) and
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mental health specialists (eg, psychologists, psychiatric
nurses, social workers) delivered most of the educational
interventions. Psychologists with different levels of clinical
experience and training delivered most of the psychological
and self-management interventions. Two interventions (8%)
included peer coaches with epilepsy.31,46 One pragmatic
design (4%) left the delivery of the educational intervention
to the treating physician.44
3.2 | Trial quality
The ROB assessment is summarized in Table 2. All studies
were subject to at least 1 form of bias, as described below.
3.2.1 | Allocation (selection bias)
The majority of studies (71%) reported an adequate method
of random sequence generation. Reasons for a rating as
high ROB included quasirandomized trial designs such as a
matched design (n = 1, 4%),33 alternating assignment
(n = 1, 4%),45 and allocation based on participants’ appli-
cation to 1 of 2 available courses and availability of spaces
in offered courses in a WLC design (n = 2, 8%).38,42 One
study30 was rated with very serious ROB because the allo-
cation depended on the participants’ “feasibility to attend
the meetings.” The majority of the studies reported proper
procedure for allocation concealment.
3.2.2 | Blinding (performance bias and
detection bias)
Blinding of participants and personnel is almost impossible
to achieve when studying psychological treatments; hence
the majority of studies had a high ROB (92%). Four studies
(17%)34–36,39 managed to blind the participants in both the
treatment group and the active control group by telling
TABLE 2 Summary of risk of bias assessment
Study
Random sequence
generation
Allocation
concealment
Blinding of
participants &
personnel
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
reporting
Other
biases
Au33 ↑ ↑ ? ↓ ↓ ↓ ?
Beretta44 ↓ ↓ ↑ ↓ ↓ ↓ ?
Caller50 ↓ ↑ ↑ ↓ ↑ ↓ ↓
Chaytor26 ↓ ↓ ↑ ↓ ↑ ↑ ↓
Ciechanowski27 ↓ ↓ ↑ ↓ ↑ ↑ ↓
DiIorio45 ↑ ↓ ↑ ↑ ↑ ↓ ↓
Fraser46 ↓ ↓ ↑ ↓ ↑ ↓ ↓
Gandy28 ↓ ↓ ↑ ↑ ↑ ↓ ↓
Helde49 ↓ ↓ ↑ ↓ ↓ ↓ ?
Hosseini37 ? ? ↑ ↓ ↑ ↓ ↓
Jantzen38 ↑ ↑ ↑ ↓ ↓ ↓ ?
Lua & Neni39 ↓ ? ? ? ↓ ↓ ?
Lundgren34 ↓ ↓ ↑ ↑ ↓ ↓ ↓
Lundgren35 ↓ ↓ ↑ ↑ ↓ ↓ ↓
Martinovic29 ↓ ↓ ↓ ↓ ↓ ↑ ?
May & Pf€afflin40 ↓ ↑ ↑ ↓ ↑ ↓ ?
Orjuela-Rojas30 ↑ ↑ ↑ ↓ ↑ ↓ ?
Pakpour48 ↓ ? ? ? ↓ ↓ ↓
Pf€afflin43 ↓ ↓ ↑ ↓ ↑ ↓ ↓
Pramuka41 ↓ ? ↑ ↑ ↑ ↑ ↑
Rau42 ↓ ↑ ↑ ↓ ↑ ↓ ↓
Schr€oder32 ↓ ↓ ↑ ↓ ↑ ↓ ↓
Tang36 ↓ ↓ ↑ ↓ ↓ ↓ ↓
Thompson31 ? ↑ ↑ ? ↑ ↑ ↓
Yadegary47 ↓ ? ? ? ? ↓ ↑
↓, low risk of bias; ↑, high risk of bias; ? = unclear risk of bias.
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them that they would participate in an intervention to
improve coping with epilepsy. There were no personnel
involved to be blinded in 2 studies (8%) investigating a
Web-based intervention.32,45 One study (4%)29 was classi-
fied as having a very low risk as the therapists who deliv-
ered the treatment (cognitive behavioral intervention and
counseling as usual) were blinded to the participants’ group
status; the researchers told both therapists only that they
would deliver psychological means to improve coping with
epilepsy. Blinding of the assessment of patient-reported
outcome data was adequate in the majority of studies
(62%). Five studies (21%) had a high detection bias
because the personnel conducting the outcome assessment
were aware of the treatment allocation.28,34,35,41,45
3.2.3 | Incomplete outcome data (attrition
bias)
Three studies (12%)33–35 were rated as low risk because
they reported no dropout throughout. Eight studies
(33%)27,29,36,38,39,44,48,49 were rated as low risk as there
was only a small number of missing data, which were bal-
anced across the groups with justifiable reasons. A high
ROB was suggested in 10 studies (42%) because of larger
numbers of missing data (a cutoff of ≥15% for short-term
interventions <6 months and ≥20% for long-term interven-
tions of ≥6 months was applied) that were, however, bal-
anced in 1 study (4%)46 and unbalanced in 7 studies
(29%).28,30.37,41,43,45,50 One study (4%) excluded partici-
pants who had missed >1 intervention session, which indi-
cated that no intention-to-treat analysis had been
undertaken.37 An unclear risk was assigned to 1 study (4%)
that did not provide data on the attrition rate.47 There were
2 studies (8%) that reimbursed their participants for partici-
pation in the study, but these studies had a high attrition
rate nonetheless.41,45
3.2.4 | Selective reporting (reporting bias)
Sixteen studies (67%) were rated as low ROB as there was
no evidence of selective outcome reporting within the pub-
lications. Four studies (17%)26,27,29,31,41 were rated as high
ROB due to evidence of selective outcome reporting within
the publications. A rating of low ROB was confirmed
based on document review of registered protocols provided
by the authors for 9 studies (37%).32,36,40,42,44–46,49,50
3.2.5 | Other potential sources of bias
Other potential sources of biases included language bias,
selective recruitment, and fidelity to the intervention proto-
col. Language bias remained unclear. We included 1 non-
English publication, which was published in German
(4%).42 In general, we did not have enough evidence to
judge the biases in regard to selective recruitment and fide-
lity to the intervention protocol. As a result, the bias judg-
ment remained unclear in most cases. Three studies (12%),
however, provided details regarding the attempt to ensure
fidelity to the intervention protocol by employing standard
training protocols and supervision.26–28,31 Furthermore, the
risk of infidelity to the intervention protocol was consid-
ered to be relatively low whenever the therapist delivering
the intervention coincided with the developer of the inter-
vention protocol (n = 6, 25%)25–27,34,46,48,49 and very low
when the delivery of the intervention was Internet-based
only (n = 2, 8%).32,45
3.2.6 | Effects of interventions
HRQoL
The most commonly used scale for assessing HRQoL was
the Quality of Life in Epilepsy-31/-31-P/-89 (QOLIE-31/-
31-P/-89).51,52 It was used in 17 studies (71%), of which 12
(70%) were considered for meta-analyses due to satisfac-
tory methodological homogeneity.26,27,29,30,33,36,37,41,46,47,49,50
Five studies (29%) were not included in the meta-analysis
due to methodological heterogeneity regarding intervention
delivery that was not face-to-face (n = 2, 40%; Web-based
intervention delivery,32 SMS-based intervention delivery39)
or comparatively narrow intervention goals (n = 3, 60%;
decreasing medication-related problems,44 increasing medi-
cation adherence,48 increasing satisfaction with treatment
and support43). Of the 12 studies being considered for
meta-analysis, 3 studies (25%) were eventually excluded
due to the lack of raw QOLIE-89 data (n = 2)37,41 or
QOLIE-31-P data (n = 1),47 which prevented the conver-
sion of the results into the cross-study summary QOLIE-31
scores used for the meta-analysis.*
Consequently, the meta-analysis comprised data from 9
studies (37%)26–30,33,36,46,49,50 with a total of 468 partici-
pants (see studies highlighted in gray in Table 1). Due to
substantial baseline differences between intervention and
control groups, the mean change from baseline (SD) was
used for quantitative synthesis (meta-analysis) rather than
postintervention scores (SD), and required data were
sought from all study authors. Because Martinovic et al.29
only provided the total score, subscale results can only be
presented for 8 studies (89%), with a total of 440 partici-
pants. A positive mean change indicated a postintervention
improvement.
Significant differences of mean improvement between
the treatment group and the control group were found in
the total score (9 RCTs, n = 468 participants, MD = +5.68
points, 95% CI = 3.11-8.24, P < .0001, v2 P = .08,
I2 = 43%) and all subscales except social functioning (8
RCTs, n = 440 participants, MD = +2.77 points, 95%
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CI = 1.02 to 6.57, P = .15, v2 P = .98, I2 = 0%; Fig-
ures 2A-D).
1. Emotional well-being: 8 RCTs, n = 440 participants,
MD = +7.03 points, 95% CI = 2.51-11.54, P = .002,
v2 P = .02, I2 = 59%;
2. Energy/fatigue: 8 RCTs, n = 440 participants,
MD = +6.90 points, 95% CI = 3.49-10.31, P < .0001,
v2 P = 0.24, I2 = 24%;
3. Overall QoL: 8 RCTs, n = 440 participants,
MD = +6.47 points, 95% CI = 2.68-10.25, P = .0008,
v2 P = .06, I2 = 49%;
4. Seizure worry: 8 RCTs, n = 440 participants,
MD = +5.96 points, 95% CI = 2.50-9.42, P = .0007,
v2 P = .86, I2 = 0%;
5. Cognitive functioning: 8 RCTs, n = 440 participants,
MD = +3.00 points, 95% CI = 0.21, 5.78, P = .04, v2
P = .93, I2 = 0%;
6. Medication effect: 8 RCTs, n = 440 participants,
MD = 3.84 points, 95% CI = 0.28-7.41, P = .03, v2
P = .66, I2 = 0%.
Results indicated that participants in the treatment group
showed significantly more postintervention improvement in
terms of QOLIE-31 total score and 6 of 7 subscales, compared
to their counterparts in the control group. The mean improve-
ment of the total score and 3 subscales, namely, emotional
well-being, energy/fatigue, and overall QoL, exceeded the
minimally important change (MIC) threshold established by
Borghs et al.53 for a small effect size (Cohen d = 0.3), indicat-
ing a clinically meaningful postintervention improvement.53
Of the 8 studies (47%) that were excluded from the
meta-analysis, 4 studies (50%)37,39,47,48 reported significant
improvements in the treatment group when comparing the
postintervention outcomes of treatment and control groups
in terms of QOLIE total score (Table 3A). The remaining
4 studies (50%) did not report a significant difference
between postintervention total scores when comparing
treatment and control groups (Table 3A).25,32,43,44 The
potential impact of the 3 studies (25%)37,41,47 that did not
provide data that would have allowed the study to be
included in data synthesis is probably small, especially
because 2 (67%) studies37,47 also reported significantly
higher QoL in the treatment group when comparing postin-
tervention outcomes of treatment and control groups.
Eight studies (33%) used HRQoL scales other than the
QOLIE outcome measures (Table 3B). All of them showed
a nonsignificant postintervention mean difference between
the intervention and control group except for Jantzen
et al.,38 who reported that children and adolescents of the
treatment group showed a significantly greater increase on
the “social exclusion” subscale in DISABKIDS, indicating
better QoL, compared to the controls (Table 3B).
3.2.7 | Psychiatric comorbidities outcome
measures
Depression
A total of 11 studies (46%) measured depressive symptoms
as an outcome measure. The most commonly used scale
was the Beck Depression Inventory/Beck Depression
Inventory-II, which was used in 5 studies (45%).29–32,36 All
studies indicated that there were no statistically significant
differences between the treatment and control groups at
baseline. Postintervention means were used to compare the
difference between the 2 groups. Seven studies (64%)
reported a significant postintervention difference between
the intervention and the control groups.26–29,31,32,36,46 Two
of these studies (28%) used >1 outcome measure.28,29 Four
of the 11 studies (36%) reported nonsignificant
results24,30,43,50; Caller et al.50 and Orjuela-Rojas et al.30
used >1 outcome measure (Table 4A).
Suicidal ideation
Two studies (8%) reported suicidal ideation as an outcome
measure. Whereas Ciechanowski et al.27 reported a signifi-
cantly smaller proportion of patients reporting suicidal idea-
tion at follow-up (decreasing 24% in the intervention group
FIGURE 2 Forest plots of comparisons of mean change from baseline of Quality of Life in Epilepsy (QOLIE)-31 total score and subscale
scores. A, QOLIE-31 total score. B, QOLIE-31 emotional well-being. C, QOLIE-31 energy/fatigue. D, QOLIE-31 overall quality of life. Sample size
information can be found in the columns labeled “Total.” Effect sizes are stated in the columns labeled “Mean Difference.” Five study authors
provided unpublished data to allow inclusion in the meta-analysis: Orjuela-Rojas et al.30 provided raw data to calculate the mean change from
baseline (standard deviation [SD]), Fraser et al.46 provided the mean change from baseline (SD) for the control group, Helde et al.49 provided raw
data to allow for the conversion of results from QOLIE-89 to QOLIE-31, Tang et al.36 provided all converted scores from QOLIE-31-P to QOLIE-31
and the mean change from baseline (SD), and Caller et al.50 provided unadjusted mean change from baseline (SD). Three studies did not provide
the mean change from baseline (SD).15,17,21 The mean change from baseline was calculated as a difference between pre- and postintervention
means. To calculate an adjusted SD, these 3 studies were grouped with studies investigating interventions comparable in terms of intervention
method, treatment setting (group vs individual), and total treatment time: Au et al.33 with Tang et al.,36 Ciechanowski et al.27 with Gandy et al.,28 and
Martinovic et al.29 with Orjuela-Rojas et al.30 This allowed for the calculation of the adjusted SD of the mean change from baseline based on the
correlation between pre- and postintervention means (SD) of the studies with which they were grouped. Because Martinovic et al.29 could not
provide QOLIE-31 subscale outcomes, only the total score was included from this study. CI, confidence interval; IV, inverse variance
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and increasing 12% in the usual care group [P = .025]; post-
treatment outcomes were not reported), Orjuela-Rojas et al.30
did not find a between-group difference in terms of suicide
risk using the Mini International Neuropsychiatric Interview
(intervention mean = 1.1 vs control mean = 0.6, P = .42; SD
was not reported).
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Anxiety
A total of 5 studies (21%) included anxiety level as an out-
come measure28,30,36,43,46; all of them reported no signifi-
cant baseline difference between the treatment and control
groups. The Beck Anxiety Inventory was used in 4 studies
(80%). Only Tang et al.36 reported significantly fewer anxi-
ety symptoms in the treatment group compared to control
at postintervention (P = .008; Table 4B).
TABLE 3 (A) Postintervention QOLIE-31/-31-P/-89 total scores of studies not included in meta-analysis and (B) mean postintervention
scores of all studies using health-related quality of life scales other than the QOLIE-31/-89
Study
Intervention group Control group
PMean SD Mean SD
A
QOLIE-31
Beretta44 63.00 15.48 65.04 14.38 .0070
Lua & Neni39 69.2 17.4 58.4 13.7
Pakpour48 62.14 13.21 56.01 12.12 <.001
Schr€oder32 31.72 13.37 32.56 13.37 .755
QOLIE-31-P
Yadegary47 72.18 11.34 53.49 15.97 <.001
QOLIE-89
Pramuka41 67.3 2.6 65 2.8 Not significant
Mean change SD Mean change SD P
Hosseini37 35.95 8.74 8.07 8.91 <.001
B
DiIorio45
QOLIE-10 33.8 8.0 33.3 7.5 .7310
Jantzen38
DISABKIDS Reported significant increase in the “social exclusion” subscale
Lundgren34
WHOQOL-BREF 58.4 9.7 55.3 6.6
SWLS 23.3 4.6 13.9 6.0
Lundgren35
WHOQOL-BREF 57.2 7.2 60.2 8.6
SWLS 21.8 6.3 21.0 7.1
May & Pf€afflin40
SF-36 Mental 43.7 11.5 42.5 11.8
SF-36 Physical 50.4 9.4 52.0 8.7 .0750
Rau42
KINDL 70.6 13.3 77.3 15.0 .075
Schr€oder32
WHOQOL-BREF 75.9 15.0 78.6 17.4 Not significant
Thompson31
SWLS 21.0 Not reported 18.0 Not reported .0900
A, Postintervention QOLIE-31/-31-P/-89 total scores of all 8 studies that were not included in the meta-analysis due to the uniqueness of the intervention protocol
and incompatible data. QOLIE, Quality of Life in Epilepsy; SD, standard deviation. B, QOLIE-10: Quality of Life in Epilepsy-1057; DISABKIDS: Quality of Life in
Children and Adolescents with Disabilities and Their Family54,55; WHOQOL-BREF: World Health Organization Quality of Life instrument, short version60; SWLS:
Satisfaction with Life Scale;59SF-36: Short-Form 36 (Mental: mental health, Physical: physical functioning)58; KINDL: Gesundheitsbezogene Lebensqualit€at und Psy-
chosoziale Auswirkungen der Epilepsie (Health-Related Quality of Life and Psychosocial Consequences of Epilepsy).56 The epilepsy-specific HRQoL outcome mea-
sures are highlighted in gray. References to the questionnaires’ psychometric properties and validation are included.
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3.2.8 | Seizure-related outcomes
A total of 9 studies (37%) had seizure-related variables
as an outcome measure.26,27,33–36,38,40,42,48 Seizure-related
outcomes included seizure frequency, seizure severity,
and seizure index (seizure frequency 9 seizure duration
in seconds) as operationally defined by Lundgren
et al.34,35 Three studies (33%) reported a significantly
greater reduction of seizure frequency in the treatment
compared to the control group at postintervention,34,36,40
whereas the other 5 studies (55%) found no significant
differences between the groups.26,27,33,35,38,42 In terms of
seizure severity, Pakpour et al.48 reported a significantly
greater reduction in the treatment group compared to
controls at postintervention using the Liverpool Seizure
Severity Scale, whereas Tang et al.36 reported no signifi-
cant group differences using the Seizure Severity Index.
Significantly greater reduction in terms of seizure index
in the treatment group at postintervention compared to
controls was reported in both studies by Lundgren
et al.34,35 (Table 5).
4 | DISCUSSION
This critical review yielded a meta-analysis consisting of 9
RCTs with 468 participants that indicated significant
postintervention improvement for the total scores and 6 of
TABLE 4 (A) Mean postintervention scores of depression outcomes and (B) mean postintervention scores of anxiety outcomes
Study
Intervention group Control group
PMean SD Mean SD
A
Gandy28 HADS-D 4.58 3.59 5.5 5.26 .048
Orjuela-Rojas30 5.4 Not reported 5.2 Not reported .93
Pf€afflin43 9% with HADS-D ≥ 11 5.5% with HADS-D ≥ 11 Nonsignificant
Martinovic29 BDI/BDI-II 5.4 2.97 7.8 2.66 <.05
Schr€oder32 15.84 13 18.37 10.23 .01
Thompson31 5.5 Not reported 10.6 Not reported <.01
Orjuela-Rojas30 17.2 Not reported 14.6 Not reported .58
Mean 95% CI Mean 95% CI P
Tang36 6.9 4.49, 9.31 9.47 6.26, 12.67 .045
Fraser46 PHQ-9 6.3 5.5 8.6 6 .02
Gandy28 NDDI-E 14.3 3.4 16.48 3.81 .045
Martinovic29 CES-D 9.8 4.2 13.6 4.64 <.05
HAMD 3.3 1.29 5.8 1.98 <.05
May & Pf€afflin40 D-S’ 13.63 8.99 12.22 8.86 Nonsignificant
Mean change SD Mean change SD P
Caller50 NDDI-E 0.4 0.6 0.7 0.8 .3000
Caller50 PHQ-9 0.7 1 1.2 1.2 Nonsignificant
Ciechanowski27 and Chaytor26 HSCL-20 0.18 0.7 0.48 0.7 .09
B
Gandy28 HADS-A 6.11 2.96 7.45 3.78 .089
Orjuela-Rojas30 9.7 Not reported 9.2 Not reported .800
Pf€afflin43 20.9% with HADS-A ≤ 11 17.8% with HADS-A ≥ 11 Nonsignificant
Fraser46 GAD-7 5.4 6.6 6.1 5.1 .282
Mean 95% CI Mean 95% CI
Tang36 BAI 9.73 6.35, 13.22 10.7 7.24, 14.16 .008
BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; CES-D, Center for Epidemiologic Studies Depression; CI, confidence interval; D-S’, Depressive
Mood Scale; GAD-7, Generalized Anxiety Disorder-7; HADS-A, Hospital Anxiety Depression Scale (Anxiety); HADS-D, Hospital Anxiety Depression Scale
(Depression); HAMD, Hamilton Depression Scale; HSCL-20, Hopkins Symptom Checklist-20; NDDI-E, Neurological Depressive Disorders Inventory-Epilepsy;
PHQ-9, Patient Health Questionnaire-9; SD, standard deviation.
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7 QOLIE-31 subscales. The mean improvement of the total
score and 3 subscales, namely, emotional well-being,
energy/fatigue, and overall QoL, exceeded the MIC thresh-
old established by Borghs et al.53 for a small effect size
(Cohen d = 0.3), indicating a clinically meaningful postin-
tervention improvement. Although the 2008 Cochrane
Review17 found no reliable evidence for the efficacy of
psychological treatment in PWE, this reappraisal, with
many new intervention studies in the past decade, draws a
more optimistic conclusion that psychological treatments
can be beneficial to adults with epilepsy in terms of
improved HRQoL. Furthermore, this pattern of improve-
ment was reported by 4 additional RCTs that were
excluded from our meta-analysis.
In terms of psychiatric symptoms and seizure-related
outcomes, the majority of studies (n = 7 of 11) examining
depressive symptoms reported more improvement in the
treatment (significant decrease in depressive symptoms)
compared to the control group. In contrast, only 1 of 5
studies examining anxiety found a significantly greater
reduction of anxiety symptoms in the treatment condition
compared to control at postintervention. Slightly more than
half of the studies (n = 5 of 9) investigating seizure-related
outcomes reported significantly better seizure control in the
treatment condition compared to control at posttreatment,
although 2 studies by the same leading author used an out-
come parameter that was not a validated tool.34,35
4.1 | Agreement with other studies or
reviews
The results of this review reinforce the conclusions of a
recent systematic review of psychological treatments for
epilepsy,16 which suggested that cognitive-behavioral ther-
apy and mindfulness-based interventions have consistently
demonstrated significant effects on improving HRQoL in
prospective uncontrolled as well as in controlled study
designs. Furthermore, this review is in keeping with a sys-
tematic review of cognitive behavior therapy for depression
in PWE18 that suggested interventions tailored toward
improving depression are possibly efficacious. Our results
are also in line with the previous Cochrane Review17 with
respect to a lack of reliable support for the efficacy of psy-
chological treatments in controlling seizures.
4.2 | Overall completeness and applicability
of evidence
The studies in this review evaluated complex psychological
treatments typically applied in tertiary care settings and
involved patient groups with different underlying epilepsy
diagnoses, severities of psychiatric and somatic comorbidi-
ties, and cultural, ethnic, and socioeconomic backgrounds.
There were differences between the included studies in their
stated treatment methods, goals, strategies, and theoretical
underpinnings. Psychologists with varying levels of experi-
ence delivered most of the treatments; team efforts including
a wider range of specialists (doctors, nurses, social workers,
etc) were involved in some education interventions. In some
cases, the work of these therapists was carefully structured
and supervised based on specific treatment protocols,
whereas some studies presumably relied on briefer training
courses. Nine different outcome measures had been used to
investigate our primary outcome. Hence, the efforts to extract
data for meta-analysis were hampered to some extent by the
wide diversity of outcome measures. These circumstances
were addressed by focusing our meta-analysis mainly on
psychological and self-management interventions, convert-
ing QOLIE-31-P and QOLIE-89 to QOLIE-31 if the neces-
sary raw data were provided, and analyzing the mean change
from baseline. We have no reason to believe that the results
from this meta-analysis should not be applicable in similar
settings and patient groups. Unfortunately, the variability of
outcome measures has plagued efforts to review and critique
TABLE 5 Mean postintervention scores of seizure outcomes
Study Measure
Intervention group Control group
PMean SD Mean SD
Lundgren34 Mean seizures/mo 0.71 0.91 6.00 3.91 <.001
May & Pf€afflin40 2.77 1.64 2.74 1.62 <.041
Pakpour48 LSSS 47.24 17.41 58.09 21.75 <.05
Lundgren34 Seizure indexa 23 35 2087 3539 <.001
Lundgren35 62 104 15 23 <.05
Mean 95% CI Mean 95% CI
Tang36 Mean seizures/6 wk 5.9 2.88-8.92 7.33 3.46-11.21 .018
SSI 2.55 2.06-3.03 2.91 2.44-3.38 >.05
CI, confidence interval; LSSS, Liverpool Seizure Severity Scale; SD, standard deviation; SSI, Seizure Severity Index.
aSeizure frequency 9 seizure duration in seconds.
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the psychological treatment literature,61 and development
and use of common data elements for psychological research
trials is recommended.62
Because many psychological treatments involve patient-
oriented goal setting, it would be interesting to explore
whether the extended QOLIE-31-P would provide a more
accurate reflection of the treatment effects due to the indi-
vidually weighted calculation of scores with regard to the
individual’s subjective evaluation. This exploration would
require the correlation of this extended version with quanti-
tative and qualitative clinical data in trials investigating
psychological treatments. No pediatric RCTs were included
in the meta-analysis due to lack of epilepsy-specific
HRQoL outcomes. The use of HRQoL outcomes for which
an MIC has been established allows for the evaluation of
the clinical relevance in addition to statistical outcomes.
The percentage of participants whose results reached MIC
was only provided in 1 study.36 The recent validation of
the PedsQL Epilepsy Module may provide a necessary psy-
chometrically sound HRQoL outcome for pediatric trials.63
4.3 | Quality of reporting
In many cases, the trial quality and its implementation were
better than the actual publication suggested. This is easily
understandable in studies that were published prior to the
update of CONSORT guidelines for nonpharmacologic
studies by Schulz et al.64 During our review process, the
ROB assessments were shared with all study authors and
their methodological details were clarified. Thirteen authors
contributed additional information that had been omitted or
remained unclear in the publication.
4.4 | Implications for research
Although there is a growing body of research to support use
of psychological interventions in individuals with epilepsy,
particularly adults, several research gaps still remain.
Well-designed multisite RCTs that employ evidence-based
interventions and standardized behavioral health outcome
measures appropriate to the intervention components are nec-
essary to evaluate the benefit of psychological interventions.
A recent commentary in Epilepsy & Behavior highlights
considerations and challenges to conducting and reporting
on psychological RCTs in adult and pediatric epilepsy and
offers potential solutions for improving the quality of
evidence.62
4.5 | Limitations
There are some fundamental limitations in reviewing RCTs
on using psychological treatment for epilepsy. First, the
feasibility of using RCTs to study psychological
interventions has been challenged repeatedly. It is question-
able that the multifaceted characteristics, including clinical
factors, psychological readiness, motivation, and psy-
chopathological states can be realistically balanced across
intervention and control groups.65 Furthermore, it has been
demonstrated that only a small percentage of the therapeu-
tic effect in face-to-face psychological treatment could be
attributed to treatment methods and treatment strategies.
One of the strongest therapeutic components was suggested
to be therapeutic relationship and working alliance.66,67
None of the studies investigating face-to-face psychological
interventions in this review has included these as variables,
which prevents the comparative investigation of their con-
tribution to outcome variance. Another limitation of the
meta-analysis is that the majority of available studies
focused on adults with epilepsy; therefore, our overall con-
clusions should not be generalized to the pediatric popula-
tion. Seventeen studies (71%) exhibited larger amounts of
missing data, although their participants were reimbursed
for study participation.29,33 High attrition rates challenge
the feasibility of psychological treatments, because they
require motivation and active participation. One additional
limitation is the timeliness of reviews that are copublished
with the Cochrane Review system. This review will be
updated in 2-3 years to include newer psychological trials.
4.6 | Quality of evidence
Although studies included in this review had a range of
limitations, most trials were rated as having low ROB in
terms of randomization procedures, allocation concealment,
blinding of assessors, and selective reporting. A high or
unclear ROB was assigned in half of our studies due to
attrition bias. This appeared to be a common limitation in
psychological intervention studies, as participants’ motiva-
tion and cooperation are highly important but unpre-
dictable. Blinding of participants was performed in only 4
studies.34–36,39 Blinding of therapists is intrinsically diffi-
cult in psychological intervention studies, but it was never-
theless achieved by 1 study, in which the therapists were
not aware of the study hypotheses.29 In general, we did not
have enough evidence to judge the biases in regard to
selective recruitment and fidelity to the intervention proto-
col. We limited the meta-analysis to fairly similar interven-
tions to avoid methodology heterogeneity. Even so, the
inclusion of complex multicomponent interventions with
diverse primary treatment goals still resulted in substantial
clinical and statistical heterogeneity and the quality of evi-
dence of the meta-analysis was downgraded by a few seri-
ous risks of bias in some of the studies (eg, Orjuela-Rojas
et al.30 with 4 high-risk and 1 unclear rating of a total of 7
ROB parameters). Because the majority of included studies
had at least some bias issues, we did not perform a
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sensitivity analysis comparing studies with low ROB with
studies with high ROB. Considering the above, we are
moderately confident in the effect estimate that psychologi-
cal interventions and self-management interventions may
enhance overall QoL in PWE, and in subdomains of epi-
lepsy-related QoL, namely energy/fatigue, overall QoL, and
emotionally well-being. In conclusion, the analysis reveals
that in the past 10 years, psychological interventions have
demonstrated improvement in QoL in PWE. Results of this
meta-analysis support the use of psychological interven-
tions as an adjunctive treatment for adults with epilepsy.
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ENDNOTE
* Seven of 9 studies used the QOLIE-31. Conversion to QOLIE-31
total score and subscales was needed for 1 study that used
the QOLIE-31-P and 1 study that used the QOLIE-89. For the
QOLIE-31-P, conversion was performed by recalculation using
the QOLIE-31 scoring manual and algorithm while excluding the
patient-weighted items. For the QOLIE-89, conversion to QOLIE-31
was performed by reorganizing single items into subscales based on
the QOLIE-31 scoring manual, and recalculation based on the
QOLIE-31 algorithm.
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